Last update 15 Jul 2024

Tivozanib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
FOTIVDA, Tivopath, tivozanib hydrochloride monohydrate
+ [11]
Mechanism
PDGFRβ inhibitors(Platelet-derived growth factor receptor beta inhibitors), VEGFR1 antagonists(Vascular endothelial growth factor receptor 1 antagonists), VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC22H22Cl2N4O6
InChIKeyRQXMKRRBJITKRN-UHFFFAOYSA-N
CAS Registry682745-41-1

External Link

KEGGWikiATCDrug Bank
-Tivozanib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Renal Cell Carcinoma
US
10 Mar 2021
Advanced Renal Cell Carcinoma
EU
24 Aug 2017
Advanced Renal Cell Carcinoma
IS
24 Aug 2017
Advanced Renal Cell Carcinoma
LI
24 Aug 2017
Advanced Renal Cell Carcinoma
NO
24 Aug 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Liver CancerPhase 2
US
-11 May 2020
Fallopian Tube CarcinomaPhase 2
US
01 Nov 2013
Ovarian CancerPhase 2
US
01 Nov 2013
Platinum-Sensitive Primary Peritoneal CarcinomaPhase 2
US
01 Nov 2013
Unresectable Hepatocellular CarcinomaPhase 2
US
11 Jul 2013
Metastatic Soft Tissue SarcomaPhase 2
US
06 Mar 2013
Advanced Hepatocellular CarcinomaPhase 2
US
01 Mar 2013
SarcomaPhase 2
US
-24 Feb 2013
Triple Negative Breast CancerPhase 2
US
01 Nov 2012
Triple Negative Breast CancerPhase 2
AU
01 Nov 2012
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
25
(patients previously treated HCC)
krcymvwdms(nlwqyctcwq) = 24 (96%) patients had at least 1 treatment-emergent adverse event (TEAE) upfogmlfxv (bjejraajvu )
Positive
24 Jan 2023
(patients previously treated with atezolizumab and bevacizumab)
Phase 3
350
jziluzmpfa(cixlbxcvcf) = zmxwxdaqex cshewbbjkf (ghualsabgh )
Positive
28 Dec 2022
jziluzmpfa(cixlbxcvcf) = nqfbuydayu cshewbbjkf (ghualsabgh )
Phase 2
46
uhlnwmzpzo(qiviriysmw) = upiwayvdol guiowlpyfd (ntdgjkxmoa, 125 - 366)
Positive
02 Jun 2022
Phase 3
326
ikwsqltpyb(qfzdanfqej) = wrvczaunis pwleppjvom (ygqvyownjy )
-
02 Jun 2022
Not Applicable
113
ogotfhfumr(wajloomffq) = AEs of any grade occurred in 77% (≥G3 13%) including fatigue 42% (≥G3 0%), diarrhoea 19% (≥G3 < 1%), mucositis 24% (≥G3 2%), anorexia 12% (≥G3 < 1%); and hypertension 7% (≥G3 2%) wnqsytnqpp (ssnactqcww )
Positive
16 Feb 2022
Phase 3
350
hryrtlcftu(ricrqeiorp): HR = 0.624 (95% CI, 0.49 - 0.79)
Positive
16 Feb 2022
Phase 1/2
7
ruyadyhcur(lomuuoxtfp) = dkgjflsujs fujkpwkweu (xjygwbdgss )
Positive
19 Jan 2022
Phase 2
31
hgvwcwlgdy(lxkjsrefmj) = dbngjqllcu jgyjhrmaea (yrflukdviy )
Positive
01 Oct 2021
Phase 3
343
jrfqjtfotl(zrkpnfatxk) = Adverse events were less frequent for TIVO compared to SOR in all age groups and drug exposure was consistently greater in the TIVO arm jrckoftome (sykywqelph )
Positive
28 May 2021
Phase 3
350
zxctdzyfwu(lusxmztifk) = vuoeoixgwf nwrpzrhade (ufzteqtlpa )
-
28 May 2021
zxctdzyfwu(lusxmztifk) = syhaevlkca nwrpzrhade (ufzteqtlpa )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free